Safety and efficacy of rituximab in severe juvenile dermatomyositis: Results from 9 patients from the French autoimmunity and rituximab registry

Journal of Rheumatology

Volumn 38, Issue 7, 2011, Pages 1436-1440

  Bader Meunier, Brigitte ^a   Decaluwe, Hélène ^a,b   Barnerias, Christine ^c   Gherardi, Romain ^d   Quartier, Pierre ^a   Faye, Albert ^e   Guigonis, Vincent ^f   Pagnier, Anne ^g   Brochard, Karine ^h   Sibilia, Jean ⁱ   Gottenberg, Jacques Eric ⁱ   Bodemer, Christine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF MONTREAL   (Canada)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f DUPUYTREN UNIVERSITY HOSPITAL   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h CHU PURPAN   (France)

ⁱ HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Calcinosis; Juvenile drmatomyositis; Rituximab

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BACTERIAL INFECTION; CALCINOSIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTESTINE PERFORATION; JUVENILE DERMATOMYOSITIS; LIPOMATOSIS; MALE; MULTICENTER STUDY; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; SCHOOL CHILD; TREATMENT INDICATION; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; FEMALE; FRANCE; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79960015962     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101321     Document Type: Article

References (27)

1. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12. (Pubitemid 351890413)
2. Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve 2010;41:581-92.
3. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-7. (Pubitemid 46955736)
4. Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008;75:334-7. (Pubitemid 351609418)
5. Haroon M, Devlin J. Rituximab as a first-line agent for the treatment of dermatomyositis. Rheumatol Int 2010 Mar 26. [Epub ahead of print]
6. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7. (Pubitemid 40216325)
7. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007;56:148-53. (Pubitemid 44969291)
8. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021-6.
9. Feist E, Dorner T, Sorensen H, Burmester GR. Long lasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008;35:1230-2. (Pubitemid 351813176)
10. Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008;26:887-93.
11. Rios Fernández R, Callejas Rubio JL, Sánchez Cano D, Sáez Moreno JA, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009;27:1009-16.
12. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20. (Pubitemid 40733918)
13. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107-11. (Pubitemid 47502758)
14. Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2009;2:6609.
15. Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 2010;126:e243-6.
16. Voog E, Morschhauser F, Solal-Celigny P, Benyunes MC, Multani PS, Saunders A. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691-3.
17. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-8.
18. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-17. (Pubitemid 36301957)
19. Oddis CV, Riderr LG, Reed AM, Ruperto N, Brunner HI, Konneru B, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607-15. (Pubitemid 41369088)
20. Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res 2010;62:1533-41.
21. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008;58:3585-92.
22. Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:623-7.
23. López De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009;60:1160-72.
24. Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res 2010;62:219-25.
25. Pediatric Rheumatology INternational Trials Organization. Juvenile dermatomyositis trial. [Internet. Accessed March 14, 2011.] Available from: http://www.printo.it/project-ongoing-detail.asp?ProjectID=14
26. Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil, a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 2010;62:1446-51.
27. Dagher R, Desjonquères M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2010 Dec 9. [Epub ahead of print]